{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:14:41Z","timestamp":1793319281005,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The objective of this research was to generate psychometric evidence supporting the myasthenia gravis (MG) symptoms patient-reported outcome (PRO) scales as a fit-for-purpose measure of severity of core symptoms of MG and provide information allowing their meaningful interpretation using data from a phase 3 study in MG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from the MycarinG study, a phase 3 study of rozanolixizumab in patients with generalized MG who experience moderate to severe symptoms (<jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> Identifier: NCT03971422) were analyzed with both classical test theory (CTT) and Rasch measurement theory (RMT). Meaningful within-individual change and group-level meaningful change were estimated for three MG Symptoms PRO scales using anchor- and distribution-based methods. Anchor-based methods used patient global impression of severity (PGIS) and change (PGIC) in MG symptoms as anchors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Good measurement properties of the MG Symptoms PRO scales were shown in the sample of 200 participants: good to excellent reliability (test\u2013retest and internal consistency reliability) and validity (associations between items and scores within the MG Symptoms PRO scales and between the MG Symptoms PRO scores and other clinical outcomes\u2014MG ADL, QMG score, MGC score, and MGFA classes\u2014were as expected); and the items showed good coverage of the continuum and fit to the Rasch model. Triangulation of the anchor- and distribution-based method results led to the definition of clinically meaningful within-patient improvement in scores for Muscle Weakness Fatigability (\u221216.67), Physical Fatigue (\u221220.00), and Bulbar Muscle Weakness (\u221220.00), with associated ranges. Benchmarks are also proposed for the interpretation of group-level results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The strong psychometric performance of the MG Symptoms PRO scales and the information generated to guide its interpretation supports its use in clinical trials for demonstrating the clinical benefits of new treatments targeting core symptoms of MG (muscle weakness fatigability, physical fatigue, bulbar muscle weakness, respiratory muscle weakness, and ocular muscle weakness).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1368525","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T13:59:00Z","timestamp":1719237540000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical meaningfulness and psychometric robustness of the MG Symptoms PRO scales in clinical trials in adults with myasthenia gravis"],"prefix":"10.3389","volume":"15","author":[{"given":"Antoine","family":"Regnault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Creel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/mus.27742","article-title":"The best and worst of times in therapy development for myasthenia gravis","volume":"67","author":"Benatar","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","article-title":"The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers","volume":"13","author":"Barnett","year":"2012","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2012.06812.x","article-title":"The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice","volume":"1274","author":"Burns","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The myasthenia gravis\u2010specific activities of daily living profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2\u2014assessing respondent understanding","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2014eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s13023-021-02064-0","article-title":"Development of the myasthenia gravis (MG) symptoms PRO: a case study of a patient-centred outcome measure in rare disease","volume":"16","author":"Cleanthous","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s40120-023-00464-x","article-title":"Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG symptoms PRO","volume":"12","author":"Regnault","year":"2023","journal-title":"Neurol Therapy"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","article-title":"Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores","volume":"27","author":"Coon","year":"2018","journal-title":"Qual Life Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11136-012-0175-x","article-title":"Methods for interpreting change over time in patient-reported outcome measures","volume":"22","author":"Wyrwich","year":"2013","journal-title":"Qual Life Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4065\/77.4.371","article-title":"Clinical significance consensus meeting group. Methods to explain the clinical significance of health status measures","volume":"77","author":"Guyatt","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","article-title":"Development and validation of the myasthenia gravis impairment index","volume":"87","author":"Barnett","year":"2016","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref16","first-page":"752","volume-title":"Psychometric Theory","author":"Nunnally","year":"1994"},{"key":"ref17","first-page":"567","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1097\/00005650-198903001-00015","article-title":"Effect sizes for interpreting changes in health status","volume":"27","author":"Kazis","year":"1989","journal-title":"Med Care"},{"key":"ref19","volume-title":"Studies in Mathematical Psychology: I. Probabilistic Models for Some Intelligence and Attainment Tests","author":"Rasch","year":"1960"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.4135\/9781412985598","volume-title":"Rasch Models for Measurement","author":"Andrich","year":"1988"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta13120","article-title":"Improving the evaluation of therapeutic interventions in multiples sclerosis: the role of new psychometric methods","volume":"13","author":"Hobart","year":"2009","journal-title":"Health Technol Assess"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-13-7496-8","volume-title":"A Course in Rasch Measurement Theory: Measuring in the Educational, Social and Health Sciences","author":"Andrich","year":"2019"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"ref24","year":"2023","journal-title":"Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making, Guidance for Industry, Food and Drug Administration Staff, and other Stakeholders (draft guidance). (Guidance 4)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-020-01344-w","article-title":"How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods","volume":"18","author":"Mouelhi","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/ebmental-2020-300164","article-title":"Mind the methods of determining minimal important differences: three critical issues to consider","volume":"24","author":"Devji","year":"2021","journal-title":"BMJ Ment Health"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1097\/MLR.0000000000001111","article-title":"Can methods developed for interpreting group-level patient-reported outcome data be applied to individual patient management?","volume":"57","author":"King","year":"2019","journal-title":"Med Care"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s11136-022-03297-7","article-title":"The challenges inherent with anchor-based approaches to the interpretation of important change in clinical outcome assessments","volume":"32","author":"Wyrwich","year":"2022","journal-title":"Qual Life Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1097\/MLR.0000000000001096","article-title":"A Rasch measurement theory approach to improve the interpretation of patient-reported outcomes","volume":"57","author":"Browne","year":"2019","journal-title":"Med Care"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1368525\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T13:59:07Z","timestamp":1719237547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1368525\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":29,"alternative-id":["10.3389\/fneur.2024.1368525"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1368525","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"article-number":"1368525"}}